doi: 10.3390/antiox10020272 93 FunesS
"Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." Eli Lilly and Company, 11 Dec
Hence, this case focuses on the awareness of potential co-occurrence of these two conditions, which is especially important for risk stratification for SCD
There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful
Because B12 injections are perceived as low-stakes, some facilities devote minimal attention to screening, monitoring, and emergency readiness
In some cases, products marketed as compounded GLP-1s by bad actors have been found to be counterfeit or to contain ingredients other than what is advertised meaning they may not even be real GLP-1 drugs at all